00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
16:14 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: West Nile virus In vitro and cell culture studies identified a benzenesulfonamide-based DDX3X inhibitor that could help treat West Nile viral infection. Chemical synthesis and in vitro screening of analogs of a previously reported...
03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
19:22 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 patients in the third cohort of Part A of Phase II ACHIEVE trial to treat chronic HBV infection showing that 100 mg inarigivir soproxil led to...
14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
20:58 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
16:49 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Frog studies suggest DDX21 mRNA could help treat Treacher Collins syndrome, a craniofacial disorder caused by mutations in the TCOF1 or Pol I genes. In a Xenopus embryo model of the syndrome, injection...
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
18:52 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Spring Bank reports Phase II data for HBV candidate

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 treatment-naive patients with chronic HBV infection without cirrhosis in the first cohort of the Phase II ACHIEVE trial showing that once-daily 25 mg inarigivir soproxil (formerly...